A Phase 3 Study to Evaluate Cefepime-taniborbactam Compared to Meropenem in Adults with Ventilator Associated Bacterial Pneumonia (VABP) or Ventilated Hospital Acquired Bacterial Pneumonia (vHABP)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Cefepime/taniborbactam (Primary) ; Meropenem
- Indications Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Therapeutic Use
- Acronyms CERTAIN-2
- Sponsors VenatoRx Pharmaceuticals
Most Recent Events
- 25 Mar 2025 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 30 Oct 2024 Planned End Date changed from 1 Sep 2027 to 1 Dec 2027.
- 30 Oct 2024 Planned primary completion date changed from 1 Mar 2027 to 1 Jun 2027.